Latest Conference Coverage

Exploring Repurposed Therapeutics to Treat COVID-19: Jennifer Frontera, MD

The professor of neurology at NYU Langone Grossman School of Medicine discussed what high-potential repurposed medications could be an option to treat symptoms of COVID-19 and the realistic possibility of clinical trials. [WATCH TIME: 4 minutes]

Top Priorities Within the Migraine Field: Rashmi B. Halker-Singh, MD, FAAN, and Paul Mathew, MD, DNBPAS, FAAN, FAHS

The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology discussed some of the key research needs for migraine care going forward. [WATCH TIME: 3 minutes]

Ublixtumab’s Effect on Measures of MS Disability: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center discussed the recently presented analysis on ublituximab’s effect on disability in relapsing MS and the critical need to focus on improving quality of life. [WATCH TIME: 4 minutes]

The Progress Made in Stem Cell Therapy, Regenerative Medicine: Peter J. McAllister, MD, FAAN

The medical director and chief medical officer of the New England Center for Neurology and Headache discussed notable data from the STEMTRA trial, and the progress made in the field of regenerative medicine. [WATCH TIME: 2 minutes]

Multilevel Impact Fenfluramine’s Approval Brings to Lennox-Gastaut Syndrome

As a primary investigator for fenfluramine’s pivotal phase 3 program, Kelly Knupp, MD, MSCS, FAES, provided insight on new results presented at AAN 2022, as well as the positive ripple effect its recent approval brings to patients with Lennox-Gastaut syndrome.

Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis

In addition to demonstrating significant differences in slowing functional decline, those on gamma sensory stimulation also demonstrated a significant reduction in brain atrophy relative to the sham group in the OVERTURE study.

Understanding the Associations of Stroke and COVID-19: Matthew Schindler, MD, PhD

The assistant professor of neurology at the University of Pennsylvania discussed stroke risk among patients with COVID-19 and the need to seek neurological consultation. [WATCH TIME: 3 minutes]

NeuroVoices: Justin Klee, Josh Cohen on Building AMX0035’s Case as the Next ALS Treatment

Following their data presentation on AMX0035 at AAN 2022, Justin Klee and Josh Cohen, the co-CEOs and co-founders of Amylyx Pharmaceuticals, shared their perspectives on the agent.

Tenecteplase Demonstrates Better Efficacy Outcomes Than Alteplase in Telestroke

In addition to significantly less disability observed in tenecteplase-treated patients, this group was also administered treatment 9.40 minutes faster than those on alteplase.

Relaying Messages About Long-Term Effects of COVID-19: Jennifer Frontera, MD

The professor of neurology at NYU Langone Grossman School of Medicine broke down the knowns and unknowns about long-term changes related to COVID-19, their legitimacy, and associations with neurodegenerative disorders. [WATCH TIME: 6 minutes]

Ofatumumab Shows Long-term Safety and Efficacy, Does Not Restrict COVID-19 Vaccine Immune Response

Data presented at the 2022 AAN Annual Meeting from the ALITHIOS and KYRIOS trials suggest that ofatumumab (Kesimpta; Novartis), an anti-CD20 therapy, is safe with up to 4 years of treatment and does not prevent the mounting of an immune response to mRNA vaccines.

Losmapimod Shows Significant Effect on Facioscapulohumeral Muscular Dystrophy Despite Unchanged Biomarkers

After showing several significant differences between placebo, the company has planned a phase 3 study that will assess the therapeutic in a cohort of 230 adults with FSHD.

Opioid Use Significantly Decreased on Rimegepant Regimen, Real-World Claims Suggest

Among triptan non/past use and current use patients, investigators observed refill decreases of 15.3% and 16.8%, respectively, in the 9 months following rimegepant treatment.

Episode 61: 2022 AAN Annual Meeting Highlights

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Jennifer Frontera, MD; Stephen Krieger, MD; Peter McAllister, MD; Kelly Knupp, MD, MSCS; Bruce Cree, MD, PhD, MAS; Shrujal Baxi, MD, MPH; and Indu Subramanian, MD. [LISTEN TIME: 32 minutes]

Long-Term Advantages of Fenfluramine for Lennox-Gastaut Syndrome: Kelly Knupp, MD

The pediatric neurologist and epilepsy specialist at Colorado Children’s Hospital discussed new data presented at AAN 2022 on the use of recently approved fenfluramine in patients with Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

Multiple-Source Constant-Current DBS Shows Safety, Efficacy at Long-Term Follow-Up

As a result of treatment with the Vercise Genus DBS system, patients reduced their use of anti-parkinsonian medications while maintaining improvements in quality of life.

Ubrogepant Demonstrates Several Positive Real-World Migraine Impacts in Patients With Prior Treatment Failure

Following the switch to ubrogepant, more than half of patients with migraine had reduced use of triptans and more than one-third of patients had reduced use of anti-inflammatory drugs.

The Therapeutic Advances in Efficacy for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center offer his perspective on the 3 available agents for the treatment of patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 2 minutes]

Understanding the Relationship Between Cerebral Arterial Blood Flow and Serum Neurofilament Light in MS

Dejan Jakimovski, MD, PhD, research assistant professor, Buffalo Neuroimaging Analysis Center, discussed his presentation at AAN 2022 on the associations between cerebral hypoperfusion and increased axonal pathology in MS.

Comparing Neurological Examinations of COVID-19 With Other Viral Infections: Matthew Schindler, MD, PhD

The assistant professor of neurology at the University of Pennsylvania discussed the similarities observed between the results of neurological exams in patients with COVID-19 vs other respiratory infections. [WATCH TIME: 3 minutes]

Improving Care for Adults With Intellectual and Developmental Disabilities

Seth M. Keller, MD, chair of the Section for Adults With IDDs at AAN, shared his perspective on the state of care for these individuals and the need to improve the difficulties they face when transitioning out of pediatric care.

SB623’s Potential for Traumatic Brain Injury: Peter J. McAllister, MD, FAAN

The medical director and chief medical officer of the New England Center for Neurology and Headache spoke to the phase 2 STEMTRA trial results of the stem cell treatment SB623. [WATCH TIME: 4 minutes]

GammaCore Noninvasive Vagus Nerve Stimulation Demonstrates Safety, Feasibility in Acute Stroke

All patients received 100% of the intended stimulations, with no reported deaths, stimulation site reactions, or any cases of acute coronary syndrome or symptomatic intracerebral hemorrhage.

Patients With Narcolepsy Prefer Once-Nightly FT218 Over Twice-Nightly Sodium Oxybates, Data Suggests

Among those who took their second nighttime sodium oxybate dose 4 hours after their first, 42% claimed they felt somewhat, quite a bit, or extremely groggy or unsteady the next morning.

RISE-PD Study of IPX-203 in Parkinson Disease: Robert A. Hauser, MD, MBA

The director of the Parkinson’s Disease and Movement Disorder Center at the University of South Florida detailed the data presented at AAN 2022 and IPX-203’s potential in Parkinson disease. [WATCH TIME: 3 minutes]

NeuroVoices: Elia Pestana-Knight, MD, on the Importance of Ganaxolone’s Approval in CDD

The pediatric epileptologist at Cleveland Clinic’s Epilepsy Center discussed data presented at AAN 2022 on the use of ganaxolone in CDD, as well as how its recent approval sets the stage for the future.

Satralizumab Eliminates Protocol-Defined Relapse in NMOSD, Long-Term Analysis Demonstrates

Low annualized relapse rates determined by investigator were observed and sustained over a 3.5-year period with treatment of satralizumab.

Overcoming Challenges in Neurology Associated With the COVID-19 Pandemic

In the AAN 2022 presidential plenary session, a trio of neurologists discussed a variety of issues stemming from the COVID-19 pandemic and how they impacted research efforts in neurological diseases.

Combination Agent P2B001 Shows Promise for Parkinson Disease in Phase 3 Data

The Pharma Two B therapy combines a dopamine agonist, pramipexole, and an MAO-B inhibitor, rasagiline, and has shown significant improvements on UPDRS total scores and ESS scores for untreated patients with PD.

24-hour Subcutaneous Foslevodopa/Foscarbidopa Demonstrates Several Benefits for Parkinson Disease

At week 26, patients on ABBV-951 had mean increases of 3.24 hours in ON time and decreases of 2.94 hours of OFF time, which was similar to previously reported studies.